Med Discovery announces executive R&D promotion
2010-12-20, Med Discovery appoints Christoph Kündig as Chief Scientific Officer.
Meet Med Discovery at Biotech in Europe Investor Forum and BioBusiness Network 2010.
2010-09-20, Med Discovery will participate in the Sachs Biotech in Europe Investor Forum and the BioBusiness Network 2010 meetings on September 29th and 30th..
Meet Med Discovery at BIO 2010.
2010-04-23, Med Discovery will be part of the Swiss presence at the Biotechnology Industry Organization’s annual International Convention in Chicago, May 3-6th..
Med Discovery out-licenses dermatology rights of kallikrein inhibitor
2010-03-01, Med Discovery has out-licensed all dermatology rights of its lead inhibitor to Dermadis SA..
Orphan drug designation of MDPK67b for Netherton syndrome approved
2009-11-27, Med Discovery has received a positive opinion from the EMEA on orphan medicinal product status for MDPK67b for the dermatology disorder Netherton Syndrome.
CTI awards grant for chemotherapy induced neutropenia research
2009-10-16, The University of Zürich and Med Discovery have received a grant from the CTI (Swiss federal agency for the promotion of innovation) to support their collaborative research on the use of protease inhibitors in chemotherapy induced neutropenia..
Med Discovery appoints Jean De Serres to Board of Directors
2009-10-09, Jean De Serres VP of Draximage (Kirkland, QC, Canada) joins the Board of Directors of Med Discovery.
Med Discovery participates in successful ISK 2009 conference
2009-09-04, Med Discovery was major sponsor and presenter at the 3rd International Symposium on Kallikreins and Kallikrein-related Peptidases in Munich .